Small Intestinal Bacterial Overgrowth (SIBO)

📋 Key Information Summary

📋

Small intestinal bacterial overgrowth (SIBO) is defined as an excessive proliferation of bacteria in the small intestine — typically ≥10³ CFU/mL on jejunal aspirate culture.
SIBO is increasingly recognised in Australia, particularly in patients with irritable bowel syndrome (IBS), diabetes mellitus, coeliac disease, and prior abdominal surgery.
The two primary diagnostic modalities available in Australia are glucose hydrogen breath test (G-HBT) and lactulose hydrogen-methane breath test (L-HMBT), interpreted using North American consensus criteria.
A positive breath test is defined as a rise in hydrogen ≥20 ppm above baseline within 90 minutes (glucose) or 120 minutes (lactulose), OR a methane level ≥10 ppm at any point.
Small bowel aspirate culture remains the research gold standard (≥10³ CFU/mL diagnostic) but is rarely performed in routine Australian practice due to invasiveness and cost.
Predisposing factors include motility disorders (diabetic gastroparesis, scleroderma), anatomic abnormalities (blind loops, strictures, surgical diversions), hypochlorhydria (PPI use, atrophic gastritis), and immunodeficiency.
Hydrogen-predominant SIBO is treated with rifaximin 550 mg PO TDS for 14 days — the first-line agent in Australia (PBS Authority Required for SIBO indication).
Methane-predominant overgrowth (intestinal methanogen overgrowth, IMO) requires combination therapy: rifaximin 550 mg TDS + neomycin 500 mg BD for 14 days.
Recurrent SIBO is common (up to 44%); rotating antibiotic regimens and prokinetics (low-dose erythromycin, prucalopride) to restore motility are recommended to reduce recurrence.
Identifying and addressing the underlying cause is essential for sustained remission — PPI deprescribing, surgical correction, and glycaemic optimisation in diabetes are key strategies.
Aboriginal and Torres Strait Islander peoples may face higher SIBO prevalence due to higher rates of chronic disease, limited specialist access in remote areas, and food insecurity affecting dietary management.

Introduction & Australian Epidemiology

Small intestinal bacterial overgrowth (SIBO) is a condition characterised by an abnormal increase in the number and/or type of bacteria in the small intestine, typically defined as ≥10³ colony-forming units per millilitre (CFU/mL) on culture of a small bowel aspirate. The condition leads to malabsorption, bloating, diarrhoea, and nutritional deficiency through bile acid deconjugation, mucosal inflammation, and competitive nutrient consumption.

In Australia, SIBO is increasingly recognised as a clinically significant condition. Prevalence estimates vary widely depending on the population studied and the diagnostic method used. Among patients meeting Rome IV criteria for irritable bowel syndrome (IBS), breath-test-positive SIBO is detected in approximately 30–40% — a figure consistent with international data. Australian gastroenterologists report growing referrals for breath testing, particularly in patients with refractory IBS, bloating-predominant functional bowel disorders, and coeliac disease with ongoing symptoms despite a gluten-free diet.

📊

Australian context: The prevalence of SIBO in the general Australian population is not well defined due to limited population-based studies. However, data from tertiary centres suggest clinically significant SIBO in 15–25% of patients referred for functional gastrointestinal investigations. Risk factors including type 2 diabetes (prevalence ~10% in Australia), long-term proton pump inhibitor (PPI) use, and coeliac disease (1 in 70 Australians) suggest a substantial burden.

SIBO can be categorised by the predominant gas produced: hydrogen-predominant SIBO, methane-predominant overgrowth (now termed intestinal methanogen overgrowth, IMO), and hydrogen sulphide-predominant (emerging diagnostic paradigm). This distinction is clinically important as treatment strategies differ. The microbiology of SIBO typically involves commensal organisms — Escherichia coli, Klebsiella, Enterococcus, and Streptococcus species — rather than frank pathogens, though community-acquired resistant organisms (including ESBL-producing Enterobacterales) may be encountered.

Pathophysiology

The small intestine maintains relative sterility compared to the colon through several defence mechanisms. Disruption of one or more of these mechanisms leads to SIBO:

Migrating motor complex (MMC): The phase III motor complex sweeps residual luminal contents distally during fasting (approximately every 90–120 minutes). Impairment of the MMC — as seen in diabetic autonomic neuropathy, scleroderma, or opioid use — is the single most important mechanism for SIBO development.
Gastric acid secretion: Gastric acid acts as a bactericidal barrier. Hypochlorhydria from chronic PPI therapy, atrophic gastritis, or Helicobacter pylori-related gastric atrophy permits oral flora to colonise the proximal small bowel.
Ileocaecal valve competence: The ileocaecal valve prevents colonic reflux. Surgical resection, Crohn's disease, or anatomical bypass renders this mechanism ineffective.
Intestinal immune function: Secretory IgA, Paneth cell antimicrobial peptides (defensins, lysozyme), and intact mucosal immunity control bacterial load. Immunodeficiency states (HIV, common variable immunodeficiency) predispose to SIBO.
Anatomical factors: Blind loops (post-surgical), strictures (Crohn's disease, radiation enteritis), diverticula (including duodenal and jejunal diverticulosis), and surgically created loops cause stasis and bacterial proliferation.

The consequences of SIBO include: bile acid deconjugation leading to fat malabsorption and steatorrhoea; carbohydrate fermentation causing bloating, flatulence, and diarrhoea; competitive consumption of vitamin B₁₂ and iron leading to deficiency; direct mucosal injury producing villous blunting and crypt hyperplasia; and D-lactic acidosis from carbohydrate malabsorption in extreme cases.

⚠️

Caution — PPI use: Long-term proton pump inhibitor therapy is one of the most common iatrogenic causes of SIBO in Australia. Up to 25% of patients on chronic PPIs may develop SIBO. Regular review of PPI indications (per RACGP Choosing Wisely recommendations) and deprescribing when clinically appropriate are essential preventive strategies.

Clinical Presentation & Diagnostic Criteria

Clinical Features

SIBO presents with a spectrum of non-specific gastrointestinal and systemic symptoms. The clinical picture may mimic IBS, coeliac disease, or inflammatory bowel disease:

Gastrointestinal: Bloating and abdominal distension (most common), flatulence, diarrhoea (watery or steatorrhoeic), abdominal cramping, nausea, early satiety
Nutritional: Weight loss, iron deficiency anaemia, vitamin B₁₂ deficiency (with macrocytosis), fat-soluble vitamin deficiencies (A, D, E, K), folate deficiency (paradoxically elevated in SIBO due to bacterial synthesis)
Systemic: Fatigue, brain fog, peripheral neuropathy (from B₁₂ deficiency), bone pain (from vitamin D deficiency), night blindness (from vitamin A deficiency)
Musculoskeletal: Arthralgia, myalgia — particularly in co-existent coeliac disease

💡

Diagnostic tip: Bloating that worsens significantly after carbohydrate-rich meals and improves with fasting or antibiotics should raise clinical suspicion for SIBO. Patients with refractory IBS symptoms despite standard therapy should be evaluated for SIBO.

When to Suspect SIBO

Clinical Scenario	Risk Factor Category
Type 1 or type 2 diabetes with gastroparesis	Motility disorder
Systemic sclerosis / scleroderma	Motility disorder
Chronic opioid use	Motility disorder
Post-surgical (Billroth II, Roux-en-Y, ileocaecal resection)	Anatomic abnormality
Crohn's disease with strictures	Anatomic abnormality
Jejunal or duodenal diverticulosis	Anatomic abnormality
Long-term PPI therapy (>12 months)	Hypochlorhydria
Atrophic gastritis / H. pylori-associated atrophy	Hypochlorhydria
Coeliac disease with ongoing symptoms on GFD	Motility + immune
HIV / common variable immunodeficiency	Immunodeficiency
Recurrent courses of broad-spectrum antibiotics	Dysbiosis
Irritable bowel syndrome (especially bloating-predominant)	Associated condition

Diagnosis

Diagnosis of SIBO in Australia is primarily based on breath testing, interpreted using the North American Consensus criteria. Small bowel aspirate culture, while the research gold standard, is rarely performed in routine clinical practice.

Hydrogen–Methane Breath Testing

Breath testing exploits the principle that bacteria in the small intestine ferment ingested substrates (glucose or lactulose), producing hydrogen and/or methane that is absorbed into the bloodstream and excreted via the lungs. Both glucose and lactulose substrates are available in Australia, and the choice between them involves trade-offs in sensitivity and specificity.

Parameter	Glucose Hydrogen Breath Test (G-HBT)	Lactulose Hydrogen-Methane Breath Test (L-HMBT)
Substrate dose	75 g glucose in 250 mL water	10 g lactulose in 200 mL water
Positive criterion — H₂	Rise ≥20 ppm above baseline within 90 minutes	Rise ≥20 ppm above baseline within 90–120 minutes (dual-peak pattern may be used as supportive)
Positive criterion — CH₄	Methane ≥10 ppm at any time point	Methane ≥10 ppm at any time point
Sensitivity	40–93% (limited by proximal absorption)	31–68% (dual-peak may increase sensitivity)
Specificity	44–100%	44–100%
Advantages	Higher specificity; fewer false positives; glucose absorbed in proximal small bowel	Detects distal small bowel overgrowth; assesses methane (IMO); widely available in Australia
Disadvantages	May miss distal SIBO; glucose absorbed before reaching distal jejunum	Colonic fermentation may produce false-positive early peaks; lower specificity
MBS availability	Not MBS-listed; out-of-pocket ~0–200	Not MBS-listed; out-of-pocket ~0–200

⚠️

Test preparation (North American Consensus): Patients must follow a preparatory diet for 24 hours before testing (low-fibre, low-fermentable diet — avoid bread, pasta, fruits, vegetables, legumes). Antibiotics should be avoided for ≥4 weeks prior. PPIs should be withheld for ≥1 week. Bismuth and laxatives should be withheld for ≥1 week. Fasting for ≥12 hours before the test is required. Mouthwash (chlorhexidine) should be used immediately before the test to eliminate oral flora.

Small Bowel Aspirate Culture

Aspiration and quantitative culture of small bowel contents (typically via upper endoscopy with aspiration from the jejunum under fluoroscopic guidance or enteroscopy) remains the research gold standard. A bacterial count of ≥10³ CFU/mL is diagnostic — this threshold is lower than the historical ≥10⁵ CFU/mL, reflecting updated consensus.

Advantages: Direct bacterial quantification and speciation; identification of antibiotic sensitivities; exclusion of alternative diagnoses
Limitations: Invasive (requires endoscopy); risk of contamination from oral/pharyngeal flora; poor sensitivity due to sampling error (bacteria may be patchy); not standardised in Australian practice; costly (no specific MBS item)
Commonly identified organisms: Escherichia coli, Klebsiella pneumoniae, Enterococcus spp., Streptococcus spp., Staphylococcus spp. — typically commensal organisms rather than frank pathogens

Identification of Predisposing Factors

A critical component of SIBO management is identifying and addressing the underlying predisposing cause. Without addressing the root aetiology, recurrence rates exceed 40%:

🔄

Motility Disorders

Primary driver of SIBO

Conditions Diabetic gastroparesis, systemic sclerosis, chronic intestinal pseudo-obstruction, opioid-induced dysmotility, post-viral gastroparesis

Assessment Gastric emptying scintigraphy (MBS item 12500), antroduodenal manometry (specialist referral)

🔬

Anatomic Abnormalities

Blind loops & structural issues

Conditions Billroth II gastrectomy, Roux-en-Y, jejunal diverticulosis, Crohn's strictures, radiation enteritis, ileocaecal valve resection

Assessment CT enterography (MBS item 57332), capsule endoscopy, MR enterography

💊

Hypochlorhydria

Impaired gastric acid barrier

Causes Chronic PPI use (>12 months), atrophic gastritis, H. pylori-associated gastric atrophy, pernicious anaemia

Action Review PPI indication; consider step-down to H₂RA or deprescribing; test for H. pylori

🛡️

Immunodeficiency

Impaired mucosal defence

Conditions HIV/AIDS, common variable immunodeficiency (CVID), IgA deficiency, immunosuppressive therapy

Assessment Quantitative immunoglobulins (MBS item 71132), HIV serology, CD4 count if indicated

Investigations — Summary

Available

Glucose hydrogen breath test

Higher specificity for proximal SIBO. Not MBS-listed. Requires specialist or private pathology referral.

Available

Lactulose hydrogen-methane breath test

Widely available at gastroenterology practices and private pathology. Detects methane (IMO). Not MBS-listed.

Specialist

Small bowel aspirate culture (≥10³ CFU/mL)

Research gold standard. Requires endoscopy with jejunal aspiration. Available at tertiary centres. No specific MBS item.

Available

FBC, B₁₂, folate, iron studies, vitamin D

Screen for nutritional deficiencies. B₁₂ may be low; folate may be paradoxically elevated. MBS-listed.

Available

Coeliac serology (tTG-IgA, total IgA)

Exclude coeliac disease as contributing factor. MBS-listed (MBS item 71132).

Referral

CT enterography / MR enterography

Assess for anatomic predisposing factors — strictures, diverticula, blind loops. MBS item 57332 (CT) / specialist referral (MRI).

Treatment

First-Line Antibiotic Therapy

The cornerstone of SIBO treatment is non-absorbable or minimally absorbable antibiotics aimed at reducing the intraluminal bacterial load. Antibiotic selection is guided by the predominant gas on breath testing.

Hydrogen-Predominant SIBO

💊

Rifaximin

Xifaxan® · Generic · Non-absorbable rifamycin

Adult dose 550 mg PO TDS for 14 days

Paediatric dose Not well established; limited data. Consider 10–15 mg/kg/day divided TDS (off-label)

Route Oral

Duration 14 days (standard course)

Renal adjustment Not required — minimal systemic absorption

Hepatic adjustment Caution in severe hepatic impairment (risk of systemic absorption); avoid in Child-Pugh C

Efficacy Normalisation of breath test in ~70% of patients; symptom improvement in ~50%

PBS status ⚠ PBS Authority Required

💡

Why rifaximin? Rifaximin is a minimally absorbed (<0.4%) rifamycin derivative that acts locally within the gastrointestinal lumen. It has broad-spectrum activity against gram-positive and gram-negative aerobes and anaerobes, a favourable safety profile, and minimal impact on colonic microbiota. It has a low risk of Clostridioides difficile infection compared to systemic antibiotics.

Methane-Predominant Overgrowth (Intestinal Methanogen Overgrowth — IMO)

Methane production is driven by archaea (primarily Methanobrevibacter smithii), not bacteria. Methane slows intestinal transit and exacerbates constipation. Monotherapy with rifaximin is inadequate for IMO; combination therapy is required.

💊

Rifaximin + Neomycin

Xifaxan® + Neomycin (Generic) · Combination for IMO

Adult dose Rifaximin 550 mg PO TDS + Neomycin 500 mg PO BD — both for 14 days

Paediatric dose Limited data; specialist supervision required

Route Oral

Duration 14 days (simultaneous administration)

Renal adjustment Neomycin: reduce dose or avoid in eGFR <30 mL/min — risk of ototoxicity and nephrotoxicity with systemic absorption

Hepatic adjustment Rifaximin: caution in severe impairment. Neomycin: no specific adjustment

Efficacy Normalisation of methane in ~85% of patients — superior to rifaximin alone for IMO

PBS status ⚠ Rifaximin: Authority Required ✔ Neomycin: PBS General Benefit

🚨

Neomycin caution: Neomycin is an aminoglycoside with potential for ototoxicity and nephrotoxicity. While oral neomycin is minimally absorbed in patients with intact GI mucosa, absorption increases with mucosal inflammation, renal impairment, or high doses. Monitor renal function. Avoid concurrent use with other ototoxic agents. Maximum duration: 14 days.

Alternative and Second-Line Agents

When rifaximin is unavailable, contraindicated, or ineffective, the following alternatives may be considered:

💊

Metronidazole

Flagyl® · Generic · Nitroimidazole

Adult dose 400 mg PO TDS for 14 days

Paediatric dose 7.5 mg/kg/dose TDS (max 400 mg/dose)

Renal adjustment No adjustment required; caution in severe impairment — risk of peripheral neuropathy

Notes Second-line. Higher side-effect burden (metallic taste, nausea, peripheral neuropathy, disulfiram-like reaction with alcohol). Systemic absorption.

PBS status ✔ PBS General Benefit

💊

Ciprofloxacin

Ciproxin® · Generic · Fluoroquinolone

Adult dose 500 mg PO BD for 14 days

Renal adjustment Reduce to 250–500 mg BD if eGFR 20–50; 250 mg OD–BD if eGFR <20

Notes Consider if intolerance to metronidazole. Risk of tendon injury, QT prolongation, C. difficile. Reserve for cases where benefits outweigh risks (TGA black box).

PBS status ✔ PBS General Benefit

💊

Amoxicillin-Clavulanate

Augmentin Duo® · Generic · β-lactam/β-lactamase inhibitor

Adult dose 875/125 mg PO BD for 14 days

Notes Limited evidence; may be considered in patients who cannot tolerate other agents. Systemic antibiotic — risk of C. difficile, rash.

PBS status ✔ PBS General Benefit

Rotating Antibiotic Regimens for Recurrent SIBO

Recurrence of SIBO is common — up to 44% of patients relapse within 12 months after successful initial treatment. For patients with recurrent SIBO, a rotating antibiotic strategy may be employed:

1

Initial Course

Rifaximin 550 mg TDS × 14 days (or rifaximin + neomycin for IMO). Reassess symptoms at 2–4 weeks post-treatment.

2

If Relapse (within 3 months)

Repeat rifaximin course. If two failures: switch to alternative agent — metronidazole 400 mg TDS × 14 days, or rotate between rifaximin, metronidazole, and ciprofloxacin at each recurrence.

3

Maintenance / Cycling

In refractory cases: cycling antibiotics every 4–6 weeks (e.g., rifaximin → metronidazole → ciprofloxacin → rifaximin) with 2-week-on/2-week-off pattern, alongside prokinetic therapy.

4

Herbal Alternatives

Limited evidence suggests herbal antimicrobials (berberine, oregano oil, neem) may be considered as adjuncts or alternatives, particularly for patients wishing to avoid repeated antibiotic courses. Discuss with gastroenterologist.

⚠️

Antimicrobial stewardship: Repeated courses of antibiotics for SIBO raise antimicrobial stewardship concerns. Limit antibiotic courses to clearly indicated cases with positive testing. Consider concurrent prokinetic therapy to address the underlying motility disorder and reduce recurrence, rather than relying on repeated antibiotic cycles alone.

Prokinetic Therapy

Prokinetic agents address the underlying motility impairment responsible for many SIBO cases. They should be considered as adjunctive therapy — particularly in recurrent or refractory SIBO — and continued after antibiotic courses to prevent recurrence.

💊

Erythromycin (low-dose, prokinetic)

EES® · Generic · Motilin receptor agonist

Adult dose 50–100 mg PO TDS (before meals) — lower than antimicrobial doses

Mechanism Motilin agonist — stimulates phase III MMC activity; prokinetic without antimicrobial effect at low dose

Duration Ongoing — typically 3–6 months; long-term use possible with monitoring

Adverse effects GI intolerance, QT prolongation (monitor ECG in at-risk patients), drug interactions (CYP3A4)

PBS status ✔ PBS General Benefit (at antimicrobial doses; prokinetic dose is off-label)

💊

Prucalopride

Resotran® · Selective 5-HT₄ agonist

Adult dose 1–2 mg PO OD

Mechanism Selective high-affinity 5-HT₄ receptor agonist — stimulates colonic and small bowel motility; promotes MMC

Notes Approved for chronic constipation; used off-label for SIBO prokinetic therapy. Better tolerated than erythromycin. Avoid in severe renal impairment (eGFR <30).

PBS status ✘ Not PBS listed

Addressing the Underlying Cause

Successful long-term management of SIBO requires identification and treatment of the predisposing factor. Without addressing the root cause, recurrence rates are high:

PPI deprescribing: If long-term PPI therapy is not clearly indicated (per RACGP guidelines), step down to H₂ receptor antagonists (famotidine 20 mg PO BD) or discontinue with monitoring
Diabetic optimisation: Tight glycaemic control to reduce autonomic neuropathy; consider diabetic gastroparesis management (metoclopramide, domperidone)
Surgical correction: Where anatomical factors are correctable (e.g., stricturoplasty, blind loop revision)
Opioid reduction: Taper or cease opioids if possible; consider opioid-sparing pain strategies; if ongoing use, consider peripherally acting μ-opioid receptor antagonists (naloxegol — Movantik®)
Immunodeficiency management: Treat underlying HIV; consider immunoglobulin replacement for CVID
Dietary modification: Low FODMAP diet may reduce symptoms; elemental diet has evidence for bacterial reduction; ensure adequate nutrition

Monitoring

Week 0

Commence antibiotic therapy. Baseline bloods: FBC, B₁₂, folate, iron studies, vitamin D, LFTs, eGFR (if using neomycin). Identify and document predisposing factors.

Week 2

Complete antibiotic course. Commence prokinetic if recurrent SIBO or known motility disorder. Begin addressing underlying cause (PPI deprescribing, glycaemic optimisation).

Week 4–6

Clinical review — assess symptom response. Repeat nutritional bloods if deficiencies identified. If symptoms persist, consider repeat breath test to confirm eradication.

Month 3

Repeat breath test if initial treatment response was equivocal. If recurrence confirmed: repeat antibiotic course or rotate agent. Continue prokinetic.

Month 6–12

Long-term follow-up. Monitor for recurrence (symptom diary). Annual nutritional bloods if prior deficiencies. Ongoing management of predisposing factors. Specialist review for refractory cases.

Special Populations

🤰 Pregnancy

Rifaximin

Category B3 — limited human data; animal studies show no teratogenicity. Use only if benefits clearly outweigh risks; avoid in first trimester if possible.

Neomycin

Category D — risk of ototoxicity with prolonged use. Avoid in pregnancy. If IMO treatment essential, consider rifaximin monotherapy under specialist guidance.

Metronidazole

Category B2 — generally avoided in first trimester. May be used in second/third trimester if needed.

Erythromycin (prokinetic)

Category A — safe in pregnancy. However, prokinetic dose evidence in SIBO is limited.

👶 Paediatrics

SIBO in children

SIBO is increasingly recognised in paediatric functional GI disorders, particularly in children with anatomical anomalies, neurological impairment, or recurrent abdominal pain. Lactulose breath testing may be used but normative data in children are limited.

Rifaximin

Not TGA-approved for SIBO in children <12 years. Limited paediatric data. Off-label use at 10–15 mg/kg/day divided TDS — specialist supervision required.

Metronidazole

7.5 mg/kg/dose TDS (max 400 mg/dose) for 14 days. Well-established safety profile in children.

👴 Elderly

Increased risk

Age-related decline in gastric acid secretion, higher prevalence of atrophic gastritis, increased PPI use, and higher rates of diabetes and systemic sclerosis increase SIBO risk in elderly Australians.

Rifaximin

Safe in elderly — minimal systemic absorption. No dose adjustment required.

Neomycin

Use with caution — age-related renal impairment increases risk of ototoxicity and nephrotoxicity. Check eGFR before prescribing.

🏥 Renal Impairment

Rifaximin

No dose adjustment — minimal systemic absorption. Safe in all stages of CKD.

Neomycin

Reduce dose or avoid if eGFR <30 mL/min. Monitor renal function and hearing if used. Consider alternative combination therapy.

Ciprofloxacin

Dose adjustment required: 250–500 mg BD if eGFR 20–50; 250 mg OD–BD if eGFR <20.

🫁 Hepatic Impairment

Rifaximin

Caution in severe hepatic impairment (Child-Pugh B/C) — risk of increased systemic absorption. Monitor for rifamycin-related adverse effects.

Metronidazole

Use with caution in severe liver disease — risk of encephalopathy exacerbation. Consider dose reduction.

🛡️ Immunocompromised

HIV/AIDS

SIBO prevalence is higher in HIV. Consider SIBO evaluation in patients with unexplained chronic diarrhoea despite ART. Standard rifaximin therapy applies.

CVID / IgA deficiency

Higher susceptibility to GI infections and SIBO. Immunoglobulin replacement may reduce SIBO incidence. Antibiotic therapy as per standard protocols.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Higher chronic disease burden

Aboriginal and Torres Strait Islander peoples experience higher rates of type 2 diabetes (approximately 2–3 times the non-Indigenous rate), which is a major predisposing factor for SIBO through diabetic gastroparesis and autonomic neuropathy. Earlier screening for SIBO symptoms should be considered in this population.

Helicobacter pylori prevalence

H. pylori infection rates are significantly higher in Aboriginal and Torres Strait Islander communities (particularly remote communities), contributing to chronic gastritis, hypochlorhydria, and increased SIBO risk. H. pylori eradication should be considered where identified.

Remote and rural access

Access to breath testing and gastroenterology services is severely limited in remote and very remote Australia. Telehealth gastroenterology consultations should be utilised. Where breath testing is unavailable, empiric treatment with rifaximin may be considered in patients with strong clinical suspicion and predisposing factors — in consultation with a gastroenterologist via telehealth.

PBS and medication access

Rifaximin is PBS Authority Required, which may create access barriers. Ensure PBS Authority applications are completed promptly. Alternative antibiotics (metronidazole, amoxicillin-clavulanate) are PBS General Benefit and more readily accessible in community pharmacies, including remote area pharmacies.

Environmental enteropathy

Overcrowded housing and poor environmental health infrastructure in some communities may contribute to chronic enteric infections, small bowel inflammation, and altered gut microbiome — all potential contributors to SIBO. Addressing social determinants of health (housing, water quality, sanitation) is fundamental to long-term outcomes.

Dietary considerations

Dietary management strategies for SIBO (low FODMAP, elemental diet) may be impractical in communities with limited food access, high food costs, and reliance on specific food sources. Dietary advice should be culturally appropriate and realistic. Dietitian involvement (via Medicare-funded Aboriginal Health Worker or telehealth) is recommended.

Cultural safety

Engage Aboriginal Health Workers and Aboriginal Liaison Officers in SIBO education, treatment planning, and follow-up. Provide culturally safe explanations of breath testing and treatment. Use of plain language resources and, where appropriate, interpreter services for patients whose first language is not English.

📚 References

1. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG clinical guideline: small intestinal bacterial overgrowth. Am J Gastroenterol. 2020;115(2):165–178. doi:10.14309/ajg.0000000000000505
2. Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus. Am J Gastroenterol. 2017;112(5):775–784. doi:10.1038/ajg.2017.46
3. Quigley EMM. The spectrum of small intestinal bacterial overgrowth (SIBO). Curr Gastroenterol Rep. 2019;21(1):3. doi:10.1007/s11894-019-0671-z
4. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol. 2007;3(2):112–122.
5. Rao SSC, Bhagatwala J. Small intestinal bacterial overgrowth: clinical features and therapeutic management. Clin Transl Gastroenterol. 2019;10(10):e00078. doi:10.14309/ctg.0000000000000078
6. Australian Institute of Health and Welfare (AIHW). Diabetes: Australian facts. Canberra: AIHW; 2023. Cat. no. CVD 84.
7. The Royal Australian College of General Practitioners (RACGP). Deprescribing proton pump inhibitors — evidence-based clinical practice guideline. East Melbourne: RACGP; 2023.
8. Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther. 2013;38(8):925–934. doi:10.1111/apt.12479
9. Pimentel M, Constantino T, Kong Y, Bajwa M, Rezaei A, Park S. A 14-day course of rifaximin for the treatment of constipation-predominant irritable bowel syndrome. Am J Gastroenterol. 2006;101(1):326–333. doi:10.1111/j.1572-0241.2006.00399.x
10. Low K, Hwang L, Hua J, Zhu A, Morales W, Pimentel M. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44(8):547–550. doi:10.1097/MCG.0b013e3181c64c90
11. Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SSC. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial overgrowth and its eradication. Aliment Pharmacol Ther. 2013;38(8):947–955. doi:10.1111/apt.12475
12. Gatta L, Scarpignato C. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45(5):604–616. doi:10.1111/apt.13928
13. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander health performance framework 2023 summary report. Canberra: AIHW; 2023.
14. Choung RS, Ruff KC, Malhotra A, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther. 2011;33(9):1059–1067. doi:10.1111/j.1365-2036.2011.04625.x